首页 > 最新文献

Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity最新文献

英文 中文
2022-RA-1118-ESGO Pseudomyxoma peritonei arising from mature ovarian teratoma: a case report and review of current literature 成熟卵巢畸胎瘤引起的腹膜假性粘液瘤:1例报告及文献复习
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.435
Minah Ha, Isileli Tonga, T. de Greve, J. Pickett
{"title":"2022-RA-1118-ESGO Pseudomyxoma peritonei arising from mature ovarian teratoma: a case report and review of current literature","authors":"Minah Ha, Isileli Tonga, T. de Greve, J. Pickett","doi":"10.1136/ijgc-2022-esgo.435","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.435","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79203159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-184-ESGO Acceptance, awareness and safety of COVID 19 vaccine among gynecological and breast cancer patients, a single Egyptian center experience 埃及妇科和乳腺癌患者对COVID - 19疫苗的接受度、认知度和安全性的研究
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-ESGO.395
O. M. Korani, R. Allam, Youstina Elamir, M. Rahouma, H. A. Shokralla
Introduction/BackgroundHigher risk of COVID 19 infection reported in patients with cancer. There are limited studies comparing the available vaccines in cancer patients.MethodologyStudy was conducted to 370 patients with breast and gynecological cancer. Data collected on comorbidities, cancer diagnosis, stage and treatment, COVID 19 infection, severity, timing of infection to chemotherapy, COVID 19 vaccination status, and vaccine side effects.ResultsBy March 15th 2022, 40.3% of study population had received COVID 19 vaccine, 52.2% not yet & 7.6% were refusing it. Commonest vaccine received in chemotherapy group was Sinovac 56%, Pfizer & AstraZeneca 18.7% for each, while sputnik & Johnson 1.3%, 5.3% respectively.Highest COVID 19 vaccine refusal was in elderly 71.4% P. < 0.01. Higher education patients were more likely to refuse vaccination P. < 0.03.Gynecological malignancy cases were twice higher refusal rate to COVID vaccine compared to the breast cancer cases 13.5% vs 6.1% P. <0.01.Multivariate analysis showed that CTH treatment increased risk of COVID 19 infection P. <0.001, Odds Ratio 4.6, 95% CI (2.3, 9.4).Injection site pain reported by 66.7%, fever, flu like symptoms were reported in 20.8% 12.5% respectively. Vaccine side effects reported with AstraZeneca & Pfizer 41.7%, 37.5%, respectively, while 16.7% of cases received Sinovac reported any side effects P. < 0.001.Gynecological cancer cases were at a higher risk to develop side effects post COVID 19 vaccination 29.2%, P. < 0.01 with odds ratio 3.54 and 95% CI (1.2, 10.1). 90% of reported severe COVID 19 infection were diagnosed with advanced malignancy P. <0.05.ConclusionHigher vaccination refusal reported among elder patient with advanced stage gynecological cancers. Patients with cancer have increased risk to COVID 19 infection. There are no major safety concerns to receive COVID19 vaccination during CTH.
导读/背景癌症患者感染COVID - 19的风险更高。比较癌症患者可用疫苗的研究有限。方法对370例乳腺癌和妇科肿瘤患者进行研究。收集的数据包括合并症、癌症诊断、分期和治疗、COVID - 19感染、严重程度、感染化疗时间、COVID - 19疫苗接种状况和疫苗副作用。结果截至2022年3月15日,40.3%的研究人群接种了COVID - 19疫苗,52.2%的人尚未接种,7.6%的人拒绝接种。老年人拒接种率最高,为71.4%,p < 0.01。高学历患者拒绝接种的可能性较大,p < 0.03。妇科恶性肿瘤患者对新冠肺炎疫苗的拒绝率是乳腺癌患者的2倍(13.5% vs 6.1%, p <0.01)。多因素分析显示,CTH治疗增加COVID - 19感染风险p <0.001,优势比4.6,95% CI(2.3, 9.4)。报告注射部位疼痛者占66.7%,报告发热、流感样症状者分别占20.8%和12.5%。阿斯利康和辉瑞的副作用发生率分别为41.7%和37.5%,而科华的副作用发生率为16.7%,p < 0.001。妇科癌症患者接种COVID - 19疫苗后发生不良反应的风险较高,为29.2%,p < 0.01,优势比为3.54,95% CI(1.2, 10.1)。重症感染者确诊为晚期恶性肿瘤的占90%,p <0.05。结论老年晚期妇科肿瘤患者拒种率较高。癌症患者感染COVID - 19的风险增加。在CTH期间接种covid - 19疫苗没有重大安全问题。
{"title":"2022-RA-184-ESGO Acceptance, awareness and safety of COVID 19 vaccine among gynecological and breast cancer patients, a single Egyptian center experience","authors":"O. M. Korani, R. Allam, Youstina Elamir, M. Rahouma, H. A. Shokralla","doi":"10.1136/ijgc-2022-ESGO.395","DOIUrl":"https://doi.org/10.1136/ijgc-2022-ESGO.395","url":null,"abstract":"Introduction/BackgroundHigher risk of COVID 19 infection reported in patients with cancer. There are limited studies comparing the available vaccines in cancer patients.MethodologyStudy was conducted to 370 patients with breast and gynecological cancer. Data collected on comorbidities, cancer diagnosis, stage and treatment, COVID 19 infection, severity, timing of infection to chemotherapy, COVID 19 vaccination status, and vaccine side effects.ResultsBy March 15th 2022, 40.3% of study population had received COVID 19 vaccine, 52.2% not yet & 7.6% were refusing it. Commonest vaccine received in chemotherapy group was Sinovac 56%, Pfizer & AstraZeneca 18.7% for each, while sputnik & Johnson 1.3%, 5.3% respectively.Highest COVID 19 vaccine refusal was in elderly 71.4% P. < 0.01. Higher education patients were more likely to refuse vaccination P. < 0.03.Gynecological malignancy cases were twice higher refusal rate to COVID vaccine compared to the breast cancer cases 13.5% vs 6.1% P. <0.01.Multivariate analysis showed that CTH treatment increased risk of COVID 19 infection P. <0.001, Odds Ratio 4.6, 95% CI (2.3, 9.4).Injection site pain reported by 66.7%, fever, flu like symptoms were reported in 20.8% 12.5% respectively. Vaccine side effects reported with AstraZeneca & Pfizer 41.7%, 37.5%, respectively, while 16.7% of cases received Sinovac reported any side effects P. < 0.001.Gynecological cancer cases were at a higher risk to develop side effects post COVID 19 vaccination 29.2%, P. < 0.01 with odds ratio 3.54 and 95% CI (1.2, 10.1). 90% of reported severe COVID 19 infection were diagnosed with advanced malignancy P. <0.05.ConclusionHigher vaccination refusal reported among elder patient with advanced stage gynecological cancers. Patients with cancer have increased risk to COVID 19 infection. There are no major safety concerns to receive COVID19 vaccination during CTH.","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87444832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-880-ESGO Impact of COVID-19 on waiting times in the gynaecological cancer patient pathway, a comparative study 2019冠状病毒病对妇科癌症患者路径等待时间影响的比较研究
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-ESGO.415
Natasha Victoria Craig, H. Pierce, Michelle Ann Louise Godfrey, S. Stezaker, F. Gardner
Introduction/BackgroundWe set out to quantify the effect of the COVID-19 pandemic on waiting times experienced by patients referred to a tertiary gynae-oncology service at Queen Alexandra Hospital, Portsmouth by comparing waiting times, before and during, the pandemic.MethodologyAll gynaecological cancer diagnoses over two five-month periods 1/2/2019 – 30/6/2019 (the pre-Covid period), and during the initial pandemic period 1/2/2020 – 30/6/2020, (during Covid), were tracked from referral date onwards throughout the patient pathway, and waiting times (average number of days) compared. Patients receiving private care, with a diagnosis prior to formal referral or having chemo or radiotherapy prior to surgery were excluded.ResultsThere were 131 gynaecological cancer diagnoses in the pre-Covid period, and 87 during Covid. Waiting time from referral to see a specialist was 13.1 days pre-Covid, and 10.9 during Covid (p=0.08). Time from referral to imaging (CT/MRI) was similar between the two groups (29.0 vs 25.6 during Covid, p=0.36). Time from referral to diagnosis was significantly shorter during Covid (34.9 vs 23.7 days during Covid, p = 0.0017). 74 patients (pre-Covid) and 51 (during Covid) underwent surgery as their primary treatment. Waiting time from decision to treat to operation date was similar between the two groups (29.5 vs 24.2 days during Covid, p=0.13). Waiting time from initial referral to surgery was significantly shorter during the pandemic (55.5 vs 42.5 during Covid, p=0.001).ConclusionCancer diagnoses at this centre were a third less than the same time the previous year. Unlike benign gynaecological services, resourcing for gynae-oncology services remained consistent throughout the pandemic. The reduced patient volumes meant those in the pathway had improved care in the form of quicker diagnoses and surgery. These findings suggest that Covid-related challenges in the gynae-oncology care pathway were pre-hospital, possibly related to reduced presentations, GP access and or referrals.
介绍/背景我们着手通过比较大流行之前和期间的等待时间,量化COVID-19大流行对朴茨茅斯亚历山德拉皇后医院三级妇科肿瘤服务的患者等待时间的影响。方法:从转诊日期开始跟踪2019年2月1日至2019年6月30日(Covid前)和2020年2月1日至2020年6月30日(Covid期间)两个5个月期间的所有妇科癌症诊断,并比较等待时间(平均天数)。接受私人护理、在正式转诊前诊断或在手术前接受化疗或放疗的患者被排除在外。结果确诊前131例妇科肿瘤,确诊后87例。从转诊到看专家的等待时间在Covid前为13.1天,在Covid期间为10.9天(p=0.08)。两组之间从转诊到成像(CT/MRI)的时间相似(Covid期间29.0 vs 25.6, p=0.36)。新冠肺炎期间从转诊到诊断的时间明显缩短(34.9天vs 23.7天,p = 0.0017)。74名患者(新冠肺炎前)和51名患者(新冠肺炎期间)接受了手术作为主要治疗。从决定治疗到手术日期的等待时间在两组之间相似(Covid期间29.5天和24.2天,p=0.13)。大流行期间,从初次转诊到手术的等待时间明显缩短(55.5比42.5,p=0.001)。结论该中心的癌症诊断率比去年同期下降了三分之一。与良性妇科服务不同,在整个大流行期间,妇科肿瘤服务的资源供应保持一致。病人数量的减少意味着那些在这条通路上的人得到了更快的诊断和手术,从而改善了护理。这些发现表明,在妇科肿瘤护理途径中,与新冠病毒相关的挑战是院前的,可能与就诊次数减少、全科医生就诊和/或转诊有关。
{"title":"2022-RA-880-ESGO Impact of COVID-19 on waiting times in the gynaecological cancer patient pathway, a comparative study","authors":"Natasha Victoria Craig, H. Pierce, Michelle Ann Louise Godfrey, S. Stezaker, F. Gardner","doi":"10.1136/ijgc-2022-ESGO.415","DOIUrl":"https://doi.org/10.1136/ijgc-2022-ESGO.415","url":null,"abstract":"Introduction/BackgroundWe set out to quantify the effect of the COVID-19 pandemic on waiting times experienced by patients referred to a tertiary gynae-oncology service at Queen Alexandra Hospital, Portsmouth by comparing waiting times, before and during, the pandemic.MethodologyAll gynaecological cancer diagnoses over two five-month periods 1/2/2019 – 30/6/2019 (the pre-Covid period), and during the initial pandemic period 1/2/2020 – 30/6/2020, (during Covid), were tracked from referral date onwards throughout the patient pathway, and waiting times (average number of days) compared. Patients receiving private care, with a diagnosis prior to formal referral or having chemo or radiotherapy prior to surgery were excluded.ResultsThere were 131 gynaecological cancer diagnoses in the pre-Covid period, and 87 during Covid. Waiting time from referral to see a specialist was 13.1 days pre-Covid, and 10.9 during Covid (p=0.08). Time from referral to imaging (CT/MRI) was similar between the two groups (29.0 vs 25.6 during Covid, p=0.36). Time from referral to diagnosis was significantly shorter during Covid (34.9 vs 23.7 days during Covid, p = 0.0017). 74 patients (pre-Covid) and 51 (during Covid) underwent surgery as their primary treatment. Waiting time from decision to treat to operation date was similar between the two groups (29.5 vs 24.2 days during Covid, p=0.13). Waiting time from initial referral to surgery was significantly shorter during the pandemic (55.5 vs 42.5 during Covid, p=0.001).ConclusionCancer diagnoses at this centre were a third less than the same time the previous year. Unlike benign gynaecological services, resourcing for gynae-oncology services remained consistent throughout the pandemic. The reduced patient volumes meant those in the pathway had improved care in the form of quicker diagnoses and surgery. These findings suggest that Covid-related challenges in the gynae-oncology care pathway were pre-hospital, possibly related to reduced presentations, GP access and or referrals.","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80371779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-744-ESGO Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative 乙型肝炎筛查降低在地区三级癌症中心接受化疗的妇科肿瘤患者病毒再激活的风险:一项质量改进倡议
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.405
S. Mah, J. Bellini, Lucy Zhao, Julie My van Nguyen, C. Reade, W. Jiménez, V. Carlson, N. K. Tyagi, L. Bernard, G. Pond, L. Eiriksson
{"title":"2022-RA-744-ESGO Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative","authors":"S. Mah, J. Bellini, Lucy Zhao, Julie My van Nguyen, C. Reade, W. Jiménez, V. Carlson, N. K. Tyagi, L. Bernard, G. Pond, L. Eiriksson","doi":"10.1136/ijgc-2022-esgo.405","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.405","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79452018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1327-ESGO Intrathecal morphine, a way to achieve opioid-free pain management within an ERAS 鞘内吗啡,一种在ERAS内实现无阿片类药物疼痛管理的方法
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.444
J. Klat, S. Bajsova, M. Romanová
{"title":"2022-RA-1327-ESGO Intrathecal morphine, a way to achieve opioid-free pain management within an ERAS","authors":"J. Klat, S. Bajsova, M. Romanová","doi":"10.1136/ijgc-2022-esgo.444","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.444","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76821689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1224-ESGO Perioperative morbidity in gynecological oncology: a single-center prospective study 妇科肿瘤围手术期发病率:一项单中心前瞻性研究
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.441
J. Anjana, S. Sambasivan, P. Rema, J. Siva Ranjith, K. Jagathnath Krishna
{"title":"2022-RA-1224-ESGO Perioperative morbidity in gynecological oncology: a single-center prospective study","authors":"J. Anjana, S. Sambasivan, P. Rema, J. Siva Ranjith, K. Jagathnath Krishna","doi":"10.1136/ijgc-2022-esgo.441","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.441","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75575023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1501-ESGO Neuroendocrine tumors of the female genital tract; a rare entity 女性生殖道神经内分泌肿瘤;罕见的实体
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.455
D. Giannoulopoulos, S. Lekka, K. Kokkali, V. Psomiadou, G. Stanc, D. Korfias, P. Giannakas, C. Iavazzo, G. Vorgias
{"title":"2022-RA-1501-ESGO Neuroendocrine tumors of the female genital tract; a rare entity","authors":"D. Giannoulopoulos, S. Lekka, K. Kokkali, V. Psomiadou, G. Stanc, D. Korfias, P. Giannakas, C. Iavazzo, G. Vorgias","doi":"10.1136/ijgc-2022-esgo.455","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.455","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74687374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-910-ESGO Malignant struma ovarii: an up-date on the current literature 卵巢恶性肿瘤:当前文献的更新
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.417
E. Giovannopoulou, K. Saliaris, Anastasios Pandraklakis, K. Lathouras
{"title":"2022-RA-910-ESGO Malignant struma ovarii: an up-date on the current literature","authors":"E. Giovannopoulou, K. Saliaris, Anastasios Pandraklakis, K. Lathouras","doi":"10.1136/ijgc-2022-esgo.417","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.417","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90399066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-217-ESGO Intravenous leiomyomatosis of the uterus with intracardiac extension: a case report 子宫静脉内平滑肌瘤病伴心内扩张1例报告
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.396
O. P. Matylevich, Mikalaj A Kurchankou, Siargei V Taranenka, V. Petukhou
{"title":"2022-RA-217-ESGO Intravenous leiomyomatosis of the uterus with intracardiac extension: a case report","authors":"O. P. Matylevich, Mikalaj A Kurchankou, Siargei V Taranenka, V. Petukhou","doi":"10.1136/ijgc-2022-esgo.396","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.396","url":null,"abstract":"","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90243735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-816-ESGO The impact of the new RCOG 2019 curriculum and COVID 19 pandemic on gynaecological training amongst the specialist trainees in the United Kingdom: a prospective study RCOG 2019新课程和COVID - 19大流行对英国专业培训人员妇科培训的影响:一项前瞻性研究
Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-ESGO.408
Anas Barakat, Ae Ismail, S. Chattopadhyay
2022-RA-816-ESGO Table 1The impact of COVID 19 pandemic on gynaecology training of respondentsModule Not at all affected Slightly affected Moderately affected Very affected Extremely affected Benign Gynaecology 6% 6% 15.8% 37.6% 34.6% Sub-fertility 14.9% 6.6% 15.7% 31.4% 31.4% Uro-gynaecology 10.3% 6.3% 14.3% 29.4% 39.7% Gynae-Oncology 16.5% 16.5% 21.3% 23.6% 22% Hysteroscopy 14.6% 18.7% 24.4% 20.3% 22% Colposcopy 22.4% 15.2% 13.6% 24% 24.8% ConclusionOur survey reveals that the new RCOG curriculum and COVID 19 pandemic have simultaneously compromised the gynaecology training amongst the UK trainees. RCOG and GMC-led more exhaustive survey would be welcomed to corporate our findings and take necessary actions. Gynaecology training amongst current trainees should be of the highest quality to optimize patient care in line with the professional skills recommended by the GMC.
表1 COVID - 19大流行对受访人员妇科培训的影响模块完全不受影响轻度影响中度影响严重影响极度影响良性妇科6% 6% 15.8% 37.6% 34.6%次生育14.9% 6.6% 15.7% 31.4% 31.4%泌尿妇科10.3% 6.3% 14.3% 29.4% 39.7%妇科肿瘤学16.5% 16.5% 21.3% 23.6% 22%宫腔镜14.6% 18.7% 24.4% 20.3% 22%阴道镜22.4% 15.2% 13.6% 24% 24.8%结论我们的调查显示新的RCOG课程和COVID - 19大流行同时影响了英国学员的妇科培训。欢迎RCOG和gmc领导的更详尽的调查将我们的发现结合起来并采取必要的行动。目前的妇科培训应该是最高质量的,以优化患者护理,符合GMC推荐的专业技能。
{"title":"2022-RA-816-ESGO The impact of the new RCOG 2019 curriculum and COVID 19 pandemic on gynaecological training amongst the specialist trainees in the United Kingdom: a prospective study","authors":"Anas Barakat, Ae Ismail, S. Chattopadhyay","doi":"10.1136/ijgc-2022-ESGO.408","DOIUrl":"https://doi.org/10.1136/ijgc-2022-ESGO.408","url":null,"abstract":"2022-RA-816-ESGO Table 1The impact of COVID 19 pandemic on gynaecology training of respondentsModule Not at all affected Slightly affected Moderately affected Very affected Extremely affected Benign Gynaecology 6% 6% 15.8% 37.6% 34.6% Sub-fertility 14.9% 6.6% 15.7% 31.4% 31.4% Uro-gynaecology 10.3% 6.3% 14.3% 29.4% 39.7% Gynae-Oncology 16.5% 16.5% 21.3% 23.6% 22% Hysteroscopy 14.6% 18.7% 24.4% 20.3% 22% Colposcopy 22.4% 15.2% 13.6% 24% 24.8% ConclusionOur survey reveals that the new RCOG curriculum and COVID 19 pandemic have simultaneously compromised the gynaecology training amongst the UK trainees. RCOG and GMC-led more exhaustive survey would be welcomed to corporate our findings and take necessary actions. Gynaecology training amongst current trainees should be of the highest quality to optimize patient care in line with the professional skills recommended by the GMC.","PeriodicalId":80519,"journal":{"name":"Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83963587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archaeologia aeliana, or, Miscellaneous tracts relating to antiquity
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1